Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-00101 for High-Grade AIN in HIV+ Patients
NCT00052897Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2002
- Primary completion
- Jul 2005
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of verpasep caltespen in anal intraepithelial neoplasia (AIN), sponsored by National Cancer Institute. Started Dec 2002; status: completed.
02
Drugs
verpasep caltespen
03
Conditions
anal intraepithelial neoplasia (AIN)
Beyond the preview
Go deeper on NCT00052897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052897.